AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s Allergan aesthetics unit is tightening up its workforce with 202 layoffs. | The layoffs at Allergan's Irvine, ...

Berkshire Hathaway, AbbVie and Intuitive Surgical beat estimates as analysts highlight growth drivers, headwinds and ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

AbbVie’s stock has tumbled nearly 13% over three months, rattled by global tariffs and the looming shadow of Humira’s patent ...

AbbVie is sprinting beyond its Humira dependency by banking on rising stars Skyrizi and Rinvoq, which are smashing sales ...

Biopharma Industry Landscape Report—uncover key trends in obesity, oncology, immunology, and AI, plus top stock picks and ...